---
layout: default
title: Mirabegron
parent: 僅模型預測 (L5)
nav_order: 93
evidence_level: L5
indication_count: 0
---

# Mirabegron
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# MIRABEGRON: Repurposing Evaluation — Insufficient Data for Full Assessment

## One-Sentence Summary

MIRABEGRON (DB08893) is currently under evaluation for drug repurposing potential; however, no original indication data and no TxGNN predicted indications were returned in this Evidence Pack.
Critical data gaps — including mechanism of action and regulatory package insert safety information — are classified as **Blocking** or **High** severity, preventing a complete evaluation at this time.
A **Hold** decision is recommended until the gaps identified below are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | No TxGNN predictions returned |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (model prediction only — no predictions available) |
| Sweden Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Mechanism of Action

Detailed mechanism of action data is not available in this Evidence Pack (Data Gap DG002, severity: High).
Without MOA information, it is not possible to assess the biological plausibility of any predicted repurposing direction or connect MIRABEGRON's pharmacological profile to a new therapeutic indication.

**Remediation required:** Query DrugBank API for DB08893 to retrieve MOA, pharmacodynamics, and target information before proceeding.

---

## Safety Considerations

Please refer to the package insert for safety information.

Package insert data was queried on 2026-03-29 (query ID 4, status: success), but warning and contraindication fields have not yet been parsed into the Evidence Pack (Data Gap DG001, severity: **Blocking**).
Drug–drug interaction data was queried and returned no results.

**Remediation required:** Download and parse the package insert PDF from the regulatory authority to extract key warnings and contraindications before advancing to safety screening Stage 1.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for MIRABEGRON contains no predicted repurposing indications, no original indication mapping, no mechanism of action, and no parsed safety data — two of which are classified as Blocking or High severity gaps that prevent any meaningful evaluation from proceeding.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Parse the package insert PDF (already retrieved on 2026-03-29) to extract key warnings, contraindications, and special population guidance; this is required before Stage 1 safety screening can begin
- **[High — DG002]** Query DrugBank API for DB08893 to retrieve MOA, pharmacological targets, and drug category; this is required for mechanistic plausibility analysis
- **[Required]** Re-run the TxGNN prediction pipeline for MIRABEGRON to populate `predicted_indications`; the current Evidence Pack contains an empty predictions array, making repurposing candidate evaluation impossible
- **[Required]** Confirm original approved indications from regulatory sources (e.g., EMA, FDA, or TFDA) and populate `original_indications` to establish the repurposing baseline
- **[Follow-up]** Once predictions are available, re-trigger evidence collection (clinical trials, literature) for the top-ranked predicted indication(s)
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

